Drug Trial Radar · NCT04768062
Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
Last checked: Nov 20, 2026Latest source record: Feb 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
74
Actual
Start
Apr 13, 2021
Primary completion
Oct 2025
Study completion Nov 2025
Sponsor
- Lead sponsor
- NS Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Nippon Shinyaku Co., Ltd.
- First posted
- Feb 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who have completed the 48-week treatment period of either viltolarsen or placebo in Study NS-065/NCNP-01-301.
Conditions
- Duchenne Muscular Dystrophy
Interventions
ViltolarsenDrug
Received during weekly intravenous infusions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment related Adverse Events as assessed by CTCAE v4.03Time frame: baseline to up to 96 weeks of treatment
Locations
31 sites in 17 countries. Site status is shown where the registry gives one.
Queensland Children's Hospital
Brisbane, Australia
The Childrens Hospital at Westmead
Westmead, Australia
CHU de Quebec Research Centre
Québec, Canada
Hospital de Niños Roberto del Rio
Santiago, Chile
Pontificia Universidad Católica de Chile
Santiago, Chile
Chinese PLA General Hospital
Beijing, China
Hunan Children's Hospital
Changsha, China
Children's Hospital of Fudan University
Shanghai, China
Shenzhen Children's Hospital
Shenzhen, China
Fakultni nemocnice Hradec Kralove
Nový Hradec Králové, Czechia
Agia Sofia Children's Hospital
Athens, Greece
Hippokration General Hospital of Thessaloniki
Thessaloniki, Greece
Fondazione Policlinico Universitario A. Gemelli - Universita Cattolica del Sacro Cuore
Rome, Italy
National Center of Neurology and Psychiatry
Tokyo, Japan
Instituto Nacional de Pediatría
Mexico City, Mexico
Leids Universitair Medisch Centrum
Leiden, Netherlands
Radboud Universitair Medisch Centrum
Nijmegen, Netherlands
New Zealand Clinical Research Ltd.
Auckland, New Zealand
Rikshospitalet
Oslo, Norway
Russian National Research Medical University
Moscow, Russia
"Saint Petersburg State Paediatric Medical University" based at Consultative and Diagnostic Centre
Saint Petersburg, Russia
Tomsk National Research Medical Center of Russian Academy of Sciences
Tomsk, Russia
Pusan National University Yangsan Hospital
Pusan, South Korea
Seoul National University Hospital
Seoul, South Korea
Hospital Sant Joan de Deu
Barcelona, Spain
Hospital Universitario La Paz
Madrid, Spain
Yeditepe University Kosuyolu Hospital
Istanbul, Turkey (Türkiye)
Birmingham Heartlands Hospital
Birmingham, United Kingdom
Royal Hospital for Children
Glasgow, United Kingdom
Royal Manchester Children's Hospital
Glasgow, United Kingdom
University College London Institute of Child Health
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.